Slate Medicines
Raleigh biotech founded in February 2026 and created with RA Capital's Sera Medicines, developing next-generation antibodies for migraine and other headache disorders; lead candidate SLTE-1009, an anti-PACAP/VIP monoclonal antibody in-licensed from DartsBio, began Phase 1 dosing in August 2026, with a PACAP/VIP x CGRP bispecific behind it.
Headquarters
Raleigh, USA
Year Founded
2026
Founders
Neil Buckley, Gregory Oakes (CEO); created with RA Capital's Sera Medicines
Country
United States
Financial Information
Funding Stage
Series A
Recent Funding
$130M
Funding By
RA Capital Management, Forbion, Foresite Capital
Core Technology
Anti-PACAP/VIP monoclonal antibodies with bispecific engineering
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: Phase 1 of SLTE-1009 (first participant dosed August 2026)
- Patents / IP Status: In-licensed from DartsBio Pharmaceuticals
Partnerships
Pharma Collaborations
RA Capital's Sera Medicines (creation partner)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
Not disclosed
Market & Differentiation
Dual-target anti-PACAP/VIP mechanism for migraine prevention with a bispecific follow-on